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Abstract
The literature that includes the study of cardiovascular complications in patients with diabetic foot syndrome was analyzed. 
The topicality of this problem is caused by the steady growth of diabetes mellitus morbidity among people. For today there are more 
than 170 mln people throughout the world with diabetes mellitus, among them 65–80 % have cardiovascular complications (myocar-
dium infarction, acute disorder of brain blood circulation and so on). 
It is established for today, that pathogenesis of diabetic foot syndrome is multi-factor one and the development of purulent-ne-
crotic stages of DFS is connected with the combination of different factors, especially microcirculation disorder. In this article we’ll 
consider the mechanisms of diabetic angiopathy development, the state of platelet-vascular hemostasis link in this category of patients. 
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1. Introduction
Diabetes mellitus (further DM) is a clinical syndrome of chronic hyperglycemia and gly-
cosuria, caused by insulin deficit that results in metabolism disorder in organs and tissues [1–3].
The diabetes is considered as the real vascular disease because of the frequent clinical man-
ifestations of arterial, cardiac, brain or peripheral complications that appear at the background of 
glycemic control worsening. 
In France the number of patients with DM is near 2,7 mln people, among them 90 % – pa-
tients with DM type 2. Near 300 000–500 000 people (10–15 %) with diabetes even do not suspect 
the presence of this disease. Moreover, the abdominal obesity is occurred in near 10 mln people that 
is a precondition of DM type 2 development. Cardio-vascular complications are revealed 2,4 times 
more often in patients with DM. They determine the prognosis of diabetes and favor the decrease 
of life-span of patients by 8 years for persons in age 55–64 years and by 4 years – for older age 
groups. In Ukraine the DM prevalence in recent 10 years increased in 1,5 times. In the structure of 
morbidity DM type 2 dominates and is 80–90 % of the whole population of patients. The most fre-
quent and serious complication of diabetes mellitus is diabetic foot syndrome (DFS) that is revealed 
in 60–80 % of patients and often results in their invalidism and death [4, 5].
Nearly in 65–80 % of cases the cause of diabetics’ lethality is cardio-vascular complica-
tions, especially myocardium infarction (MI), TEPA, acute disorder of brain blood circulation, 
acute kidney failure. After myocardium revascularization the cardiac events more often take 
place in patients with DM. The possibility of 9-years survivability after coronary intervention on 
vessels is 68 % for diabetics and 83,5 % – for ordinary people; as the result of secondary stenosis 
and aggressive atheromatosis the patients with DM suffer from the repeated MI. The share of 
patients with diabetes in cardiologic department permanently grows and is more than 33 % of all 
patients. That is why diabetes is recognized as the important separate risk factor of cardio-vas-
cular diseases formation [6–8].
For today there are more than 170 mln patients with this disease. According to the experts, 
the number of patients will grow till 2017 to 249 mln and till 2025 – to 300 mln people [9].
The world health organization determined the DM morbidity as global non-infectious epi-
demic [10].
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2. Aim of research
The analysis of accessible information sources about the features of hemostasis system in 
formation of pathology of cardio-vascular complications in patients with diabetic foot syndrome. 
3. Materials of research and their discussion 
The development of DFS complication is based first of all on the disorders of hemostasis 
system, because they precede the other disorders, typical for diabetes mellitus [11].
In the study of development of angiopathy of the lower extremities at DM the more and more 
importance is given to the changes in blood coagulation system, so the changes in both platelet- 
vascular hemostasis link and in plasma one are typical for patients with DM that, in its turn, leads 
to microcirculation disorder [12–14].
Metabolic disorders, growing at DM favor the cellular hypoxia that is a universal activating 
and injuring factor [15]. That is why the study of vascular-platelet hemostasis state becomes espe-
cially topical. 
Among the causes of diabetic anginopathies development the leading role is given to the 
raise of platelets functional activity, which molecular mechanism is explained by accumulation of ox-
ygen free radicals that leads to intensification of peroxide oxidation of the lipids of plasma and cellular 
membranes [16, 17]. The reflection of this process is the raise of malonic dialdehyde concentration, 
where it is a final product of repoxide oxidation of lipids at cyclooxigenase cascade of arachidonic acid 
in platelet membrane of patients with carbohydrate metabolism concentration [3, 18, 19]. The increase 
of glycogen quantity in cellular cytoplasm, the raise of cytoplasmatic Са+ that induces biosynthesis of 
thromboxane of blood platelets and raises the aggregation activity of platelets take place in platelets 
membrane of patients with DM as the result of metabolic disorders [20].
The change of platelet function in patients with DM leads to the decrease of membranes 
permeability, metabolic processes disorder that alongside with endothelium ability to synthesize 
anti-aggregation agents raises the risk of vascular complications [21].
According to the modern notions, pathogenesis of DM chronic complications is considered 
from the position of glucose toxicity theory, according to that, the chronically increased glucose 
level in blood is a main factor that induces the different biochemical and structural changes in cells 
and tissues [22].
Taking the view of this theory, the one of main pathogenetic mechanism of diabetic ang-
inopathy at DM type 2 is the changes in the system of hemostasis microcirculation link [23, 24].
The raise of activity of the processes of non-enzymatic glycosilation of proteins and lipo-
proteins leads to the disorder of the functions of cellular and also basal membranes of vessels. The 
change of functional activity of the components of vascular wall disturbs the normal interaction 
between endothelium cells and blood cells that favors the development of hypercoagulatory syn-
drome, changes the parameters of vascular tonus regulation and as the result leads to the vascular 
pathology development [23, 24]. 
The most role in hemocoagulatory processes development in patients with DFS is played 
by activation of plasma factors, conditioned by the active “fibrinolization” – the process of inflam-
mation and change of hemostasis plasma link at the expanse of expressed hyperfibrinogenemia 
(fibrinogen concentration raises in 1,5–2 times comparing with organism norm before fibrinolysis 
system exhaustion) [12, 25, 26]. The combination of these changes with significant activation of 
XIII factor testifies to the tendency to the most heavy hypercoagulatory changes in patients and is 
characterized with the high probability of intravascular thrombosis on the background of endothe-
lium injury. 
The other leading factor in the development of hemostasis disorders is the change of balance 
between coagulating and anti-coagulating blood systems that is proved by the essential decrease of 
antithrombin III activity and acts at microcirculation level [11, 25, 16].
The development of critical ischemia of the lower extremities is mainly connected with 
vascular factor and thrombophilia, also conditioned by the organism fibrinolization, fibrinolysis 
inhibition and deficit of activity of the natural anti-coagulation agents that is explained in first turn 
by heavy metabolic disorders and intoxication [25].
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Despite the proved inclination to the thrombus-creation at DM type I and II, the regularities 
of changes of hemostasis system indices in the age aspects were not fully studied that complicates 
the diagnostics of vascular complications. The feature of blood coagulation system in healthy peo-
ple older than 40 years is inclination to hypercoagulation. The inclination to hypercoagulation that 
is increased in young age, after 26 years is typical for patients with DM type II [27–31]. 
N. A. Nitstsa in the work, devoted to the analysis of platelet hemostasis in children with 
insulin dependent DM, made a conclusion that in children with insulin dependent DM of the differ-
ent severity and duration of disease, on the background of its compensation or subcompensation, 
the serious disorders of platelet hemostasis were revealed. These changes take place already at the 
moment of setting diagnosis and grow at the increase of disease duration that indicates the raise 
of thrombogenic potential and injury of vascular wall, starting from the disease debut and further 
increase of vascular changes [30].
The studies, carried out by G. G. Petrik and S. V. Butaev, prove that the gender differences 
are characterized with more cholesterol concentration in combination with more expressed aggre-
gation activity of platelets at DM type I, with increased fibrinogen concentration at DM type II in 
women. The essential age differences in metabolism and hemostasis parameters at DM type I and 
II were not revealed [31].
The described changes in hemostasis system occupy the one of leading places at the devel-
opment of purulent-necrotic complications of diabetic foot [32].
For today it is established, that DFS pathogenesis is multi-factor one and at the development 
of DSF purulent-necrotic stage many factors are combined, especially the microcirculation disor-
ders at the foot level [33, 34]. The series of factors take part in the formation of this link of DFS 
pathogenesis: atherosclerotic injury of great vessels, decrease of collateral blood circulation and 
reduction of vascular reserve, immune mechanisms, metabolic disorders of basal membrane of cap-
illaries, intensification of adhesive and aggregation properties of platelets and leukocytes, changes 
of erythrocytes structure and disturbance of hemocoagulatory blood properties [35].
It was proved, that fibrin and fibrinogen concentration in blood plasma and also aggre-
gation properties of platelets are increased in 78 % of patients with DFS [36]. Certainly, it 
creates conditions for microthromboses in microcirculation channel: the structure of vascular 
wall is changed, blood flow is slowed, rheological properties of blood are worsened. Normal-
ization of at least one of these factors can rather effectively reduce manifestations of puru-
lent-necrotic process in foot. 
Taking into account the fact, that fibrinolytic system of organism is directed on the natural 
lysis of fibrin, created in the process of thrombus formation, the elaboration of methods of fibrino-
lytic system correction is topical [37].
The inalienable components of fibrinolytic system that at the normal state provide the per-
manence of hemostasis and prevent the excessive thrombolysis are inhibitors of enzymes of fi-
brinolytic system. They include α2-macroglobulin and α1-antitrypsin. The complexes, created by 
these substances and plasmin, do not cause fibrinogen and fibrin breakdown but are caught by 
phagocytes of reticulendothelial system. Just the presence of these compounds in the blood plasma 
prevents the development of the uniform elements stasis and pathological microthrombosing with 
the signs of intravascular blood coagulation syndrome. At the same time fibrinolysis inhibitors not 
only provide elimination of excessive plasmin from the bloodstream but also participate in repara-
tion of tissues in macrophagic reactions [38].
It was revealed that patients with purulent-necrotic forms of DFS on the background of se-
vere intoxication are characterized with significant inhibition of platelets functions. It is manifested 
from the one side by the decrease of aggregation activity of platelets, from the other one – by the 
decrease of aggregation speed [25].
Thus, for optimization of the complex treatment of patients with purulent-inflammatory 
complication of diabetic foot it is expedient to take into account the values of biochemical and 
immunological blood parameters, to assess the inflammation process activity, the presence of en-
dogenous intoxication, the disorders of platelet-vascular hemostasis system [39–41].
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4. Conclusions
On the base of analysis of accessible scientific sources we made a conclusion that the data 
of hemocoagulation and microcirculation in patients with purulent-necrotic forms of diabetic foot 
are contradictory and the platelet-vascular hemostasis remains insufficiently studied. Like before 
the assessment of platelet-vascular hemostasis is carried out using the old, low-informative meth-
ods that do not give on-line information about the state of adhesion and aggregation of platelets, 
the problem about interconnection between platelet-vascular hemostasis with plasma one is not 
solved that essentially complicates the integral understanding of hemocoagulation in patients with 
purulent-necrotic complications of diabetic foot and the influence of its disorders on the course of 
this disease. 
It indicates the necessity of complex study of coagulation in perioperative period and differ-
ential correction of disorders that is a topical problem of anesthesiology and intensive care. 
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